Within-patient changes in serum concentrations and patient-reported outcomes following symptom-guided enzalutamide dose reduction from 160 to 120 mg

Clinical Genitourinary Cancer · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles